Compare Capital One Financial Corp. (COF) vs Eli Lilly And Co (LLY) Price & Performance

Capital One Financial (COF) trades at $217.76, down 1.02% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81 versus $4.79 expected, driven by strong revenue growth and integration progress with Discover Financial. The stock shows a P/E of 12 and net income margin of 16.96%, reflecting solid valuation and profitability metrics amid ongoing business expansion.

The outlook for COF is positive, supported by earnings momentum, synergy capture from the Discover acquisition, and analyst optimism. Key risks include integration execution, credit loss provisions, and macroeconomic pressures on consumer lending. With 63% of analysts rating it a buy, the stock presents a growth opportunity tempered by sector-specific challenges.

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.